Madrigal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Madrigal Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MDGL

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. 

CEO
William J. Sibold
CEOWilliam J. Sibold
Employees
915
Employees915
Headquarters
West Conshohocken, Pennsylvania
HeadquartersWest Conshohocken, Pennsylvania
Founded
2000
Founded2000
Employees
915
Employees915

MDGL Key Statistics

Market cap
12.47B
Market cap12.47B
Price-Earnings ratio
-39.59
Price-Earnings ratio-39.59
Dividend yield
Dividend yield
Average volume
502.74K
Average volume502.74K
High today
$517.26
High today$517.26
Low today
$502.84
Low today$502.84
Open price
$511.97
Open price$511.97
Volume
345.35K
Volume345.35K
52 Week high
$615.00
52 Week high$615.00
52 Week low
$339.31
52 Week low$339.31

Stock Snapshot

With a market cap of 12.47B, Madrigal Pharmaceuticals(MDGL) trades at $510.04. The stock has a price-to-earnings ratio of -39.59.

As of 2026-08-08, Madrigal Pharmaceuticals(MDGL) stock has fluctuated between $502.84 and $517.26. The current price stands at $510.04, placing the stock +1.4% above today's low and -1.4% off the high.

Madrigal Pharmaceuticals(MDGL) shares are trading with a volume of 345.35K, against a daily average of 502.74K.

In the last year, Madrigal Pharmaceuticals(MDGL) shares hit a 52-week high of $615.00 and a 52-week low of $339.31.

In the last year, Madrigal Pharmaceuticals(MDGL) shares hit a 52-week high of $615.00 and a 52-week low of $339.31.

MDGL News

Simply Wall St 4d
Eli Lilly Stock Rally Puts Obesity Drug Shares Under The Microscope

The race to treat obesity and metabolic disease is reshaping expectations across large pharmaceutical stocks, and Eli Lilly is front and center after its Q2 ear...

Eli Lilly Stock Rally Puts Obesity Drug Shares Under The Microscope

Analyst ratings

95%

of 19 ratings
Buy
94.7%
Hold
5.3%
Sell
0%

People also own

Based on the portfolios of people who own MDGL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.